Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations

Br J Clin Pharmacol. 1993 May;35(5):479-83. doi: 10.1111/j.1365-2125.1993.tb04173.x.

Abstract

1. Eight volunteers received in randomized order two 30 microliters drops of either 1% w/v cyclopentolate hydrochloride or a corresponding amount of cyclopentolate polygalacturonate in saline or in acetate buffer in one eye. Cyclopentolate concentrations in plasma were measured by a radioreceptor assay. 2. Peak plasma drug concentrations of about 3 ng ml-1 occurred within 30 min after all formulations. Occasionally, a second concentration peak in plasma, probably reflecting drug absorption from the gastrointestinal tract, was seen after 2 h. The mean elimination half-life of cyclopentolate was 111 min when all subjects and formulations were considered together. There were no statistically significant differences between the formulations with respect to the time-course of plasma drug concentration. 3. The maximal mydriatic effect was reached within about 15 min and was maintained for several hours, often being 1/3 of its peak value after 30 h. Similarly, an intense cycloplegic response was achieved within a few minutes, the peak changes in the near-point of vision being 9 to 10 dioptres. The cycloplegic response was more intense after one of the polygalacturonate complexes, especially at later time points.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Buffers
  • Cyclopentolate / administration & dosage
  • Cyclopentolate / pharmacokinetics*
  • Excipients
  • Eye / drug effects*
  • Female
  • Half-Life
  • Humans
  • Hydrogen-Ion Concentration
  • Male
  • Ophthalmic Solutions
  • Pectins
  • Pupil / drug effects

Substances

  • Buffers
  • Excipients
  • Ophthalmic Solutions
  • Pectins
  • Cyclopentolate
  • polygalacturonic acid